Amplia has published its new Investor Newsletter today.
This edition includes an update from our ACCENT trial - Amplia’s Phase 1b/2a clinical trial of AMP945 in people with advanced pancreatic cancer; a recap of the exciting FOLFIRINOX data from the Garvan Institute; a peek into our collaboration with the CSIRO investigating opportunities in wound healing; and more.
Read the newsletter here.
